Agios Pharmaceuticals Inc [NASDAQ: AGIO] closed the trading session at $22.34 on 2025-11-19. The day’s price range saw the stock hit a low of $22.24, while the highest price level was $25.0699.
The stocks have a year to date performance of -58.46 percent and weekly performance of -48.80 percent. The stock has been moved at -25.81 percent over the last six months. The stock has performed -48.58 percent around the most recent 30 days and changed -41.52 percent over the most recent 3-months.
If compared to the average trading volume of 654.96K shares, AGIO reached to a volume of 17612708 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Agios Pharmaceuticals Inc [AGIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGIO shares is $35.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Agios Pharmaceuticals Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on Nov-20-25. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on February 24, 2025, representing the official price target for Agios Pharmaceuticals Inc stock.
The Price to Book ratio for the last quarter was 1.01, with the Price to Cash per share for the same quarter was set at 16.34.
AGIO stock trade performance evaluation
Agios Pharmaceuticals Inc [AGIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -48.80. With this latest performance, AGIO shares dropped by -48.58% in over the last four-week period, additionally sinking by -25.81% over the last 6 months – not to mention a drop of -32.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGIO stock in for the last two-week period is set at 21.21, with the RSI for the last a single of trading hit 4.40, and the three-weeks RSI is set at 2.93 for Agios Pharmaceuticals Inc [AGIO]. The present Moving Average for the last 50 days of trading for this stock 40.38, while it was recorded at 39.83 for the last single week of trading, and 35.13 for the last 200 days.
Agios Pharmaceuticals Inc [AGIO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Agios Pharmaceuticals Inc [AGIO] shares currently have an operating margin of -1061.80% and a Gross Margin at 75.43%. Agios Pharmaceuticals Inc’s Net Margin is presently recorded at -895.86%.
Agios Pharmaceuticals Inc (AGIO) Capital Structure & Debt Analysis
According to recent financial data for Agios Pharmaceuticals Inc. ( AGIO), the Return on Equity (ROE) stands at -27.57%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -25.26%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Agios Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -30.61%, showcasing its effectiveness in deploying capital for earnings.
Agios Pharmaceuticals Inc (AGIO) Efficiency & Liquidity Metrics
Based on Agios Pharmaceuticals Inc’s (AGIO) latest financial statements, the Debt-to-Equity Ratio is 0.03%, indicating its reliance on debt financing relative to shareholder equity.
Agios Pharmaceuticals Inc (AGIO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Agios Pharmaceuticals Inc. (AGIO) effectively leverages its workforce, generating an average of -$822254.1 per employee. The company’s liquidity position is robust, with a Current Ratio of 13.82% and a Quick Ratio of 13.39%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Agios Pharmaceuticals Inc [AGIO] stock
With the latest financial reports released by the company, Agios Pharmaceuticals Inc posted -1.74/share EPS, while the average EPS was predicted by analysts to be reported at -1.63/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.11. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AGIO.
Agios Pharmaceuticals Inc [AGIO]: Institutional Ownership
There are presently around $111.06%, or 112.96%% of AGIO stock, in the hands of institutional investors. The top three institutional holders of AGIO stocks are: FARALLON CAPITAL MANAGEMENT LLC with ownership of 5.65 million shares, which is approximately 9.9547%. VANGUARD GROUP INC, holding 5.5 million shares of the stock with an approximate value of $$237.02 million in AGIO stocks shares; and VANGUARD GROUP INC, currently with $$209.52 million in AGIO stock with ownership which is approximately 8.5542%.
